Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$7.10 +1.69%

+$0.11 today

Market cap
$198.34M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.37M

Average 0.31M

DTIL Long-term Investments

Investments the company intends to hold for more than a year.

Precision BioSciences, Inc.NASDAQ: DTIL

Long-term Investments · Q1 FY2026 · quarter ended Mar 2026

Long-term investments rises 749.1% from a year ago

Long-term investments stood at $27.22M at the end of Q1 FY2026, up 749.1% from a year earlier and up 3558.7% from the prior quarter. Over 3 fiscal years it compounded at -46.1% a year.

Context

  • Long-term investments amounted to 18.9% of total assets at the end of Q1 FY2026, up 16.3 pp from a year earlier.
  • Long-term investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term investments keeps rising in the next quarterly balance sheet after a +749.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$27.22M+3558.7% QoQ
Last fiscal yearDec 2025
$744K-76.8% YoY
Year agoMar 2025
$3.21M+749.1% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+749.1%——
1 year-76.8%——
3-year CAGR-46.1%——
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
744K USD
Year-over-year change
-76.8%
4-year CAGR
-42.6%

Long-term Investments vs competitors

How DTIL compares with its peers on the latest reported figures

  • DTIL's Mar 2026 long-term investments of $27.22M is the highest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of +749.1% is the highest of 3, against a peer median of -99.8%.
  • Long-term investments amounts to 18.9% of total assets for DTIL, versus a peer median of 0.0%.
DTIL Competitors Peer median
Long-term Investments for DTIL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DTILPrecision BioSciences, Inc.Mar 2026$27.22M +749.1%-46.1%18.9%
RNAAtrium Therapeutics, Inc.Mar 2026$415K ——0.1%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$231K -99.5%—0.2%
ALECAlector, Inc.Mar 2026$0 ——0.0%
QTTBQ32 Bio Inc.Mar 2026$0 -100.0%-70.7%0.0%
GOSSGossamer Bio, Inc.Mar 2026$0 ——0.0%
HRTXHeron Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding DTIL) $0-99.8%-70.7%0.0%

Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents143.66M189.58M116.68M85.9M110.82M
Short-term Investments000413K4.76M
Net Receivables488K720K12.8M1.7M0
Inventory00000
Other Current Assets169K2.78M906K538K45K
Total Current Assets161.75M199.11M136.36M94.99M118.74M
Property, Plant & Equipment (Net)29.33M13.78M14.6M10.18M7.23M
Goodwill00000
Intangible Assets2.05M731K400K622K1.17M
Long-term Investments6.84M4.75M3.21M3.21M744K
Tax Assets00000
Other Non-current Assets11.52M19.81M5.22M27.39M26.54M
Total Non-current Assets49.74M39.06M23.42M41.4M35.68M
Total Assets211.5M238.17M159.78M136.39M154.42M
Account Payables1.14M653K2.97M1.31M296K
Short-term Debt0022.41M00
Tax Payables00000
Deferred Revenue21.24M46.19M12.04M2.96M0
Other Current Liabilities7.74M9.31M9.88M7.38M2.36M
Total Current Liabilities35.98M59.66M49.99M14.98M8.91M
Long-term Debt2.48M22.22M022.32M22.4M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)77.02M92.87M83.08M33.3M10M
Other Non-current Liabilities44K1.92M128K2.99M15.95M
Total Non-current Liabilities84.35M118.07M90.93M65.02M53.26M
Total Liabilities120.33M177.74M140.92M80M62.17M
Common Stock01K1K1K1K
Retained Earnings(316.68M)(428.31M)(489.63M)(482.46M)(528.19M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity91.17M60.43M18.86M56.39M92.25M
Total Debt9.11M24.96M31.27M30.05M28.81M
Net Debt(134.55M)(164.62M)(85.41M)(55.85M)(82.02M)

Precision BioSciences, Inc.

NASDAQ:DTIL

Intrinsic Alpha fair value

Locked

Current Price

$7.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.